Merck KGaA closes in on SpringWorks deal at $3.5B price point
Merck KGaA said Thursday that its late-stage discussions to buy the rare cancer biotech SpringWorks Therapeutics have landed on a likely price of $47 per share. That would put the value of the pending deal ...
Merck KGaA said Thursday that its late-stage discussions to buy the rare cancer biotech SpringWorks Therapeutics have landed on a likely price of $47 per share.
That would put the value of the pending deal ...
